Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction

American Journal of Cardiology

Volumn 113, Issue 8, 2014, Pages 1267-1272

  Abdallah, Mouin S ^a,b   Kosiborod, Mikhail ^a,b   Tang, Fengming ^a   Karrowni, Wassef Y ^c   Maddox, Thomas M ^d   McGuire, Darren K ^e   Spertus, John A ^a,b   Arnold, Suzanne V ^a,b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEALTH INSURANCE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; PATIENT CARE; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADULT; AGED; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NORWAY; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84897389725     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.12.040     Document Type: Article

References (28)

1. K. Franklin, R.J. Goldberg, F. Spencer, W. Klein, A. Budaj, D. Brieger, M. Marre, P.G. Steg, N. Gowda, J.M. Gore, and Investigators G Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events Arch Intern Med 164 2004 1457 1463
2. D. Aguilar, S.D. Solomon, L. Kober, J.L. Rouleau, H. Skali, J.J. McMurray, G.S. Francis, M. Henis, C.M. O'Connor, R. Diaz, Y.N. Belenkov, S. Varshavsky, J.D. Leimberger, E.J. Velazquez, R.M. Califf, and M.A. Pfeffer Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the valsartan in acute myocardial infarction (VALIANT) trial Circulation 110 2004 1572 1578
3. R. Mehran, G.D. Dangas, Y. Kobayashi, A.J. Lansky, G.S. Mintz, E.D. Aymong, M. Fahy, J.W. Moses, G.W. Stone, and M.B. Leon Short- and long-term results after multivessel stenting in diabetic patients J Am Coll Cardiol 43 2004 1348 1354
4. N.E. West, P.N. Ruygrok, C.M. Disco, M.W. Webster, W.K. Lindeboom, W.W. O'Neill, N.F. Mercado, and P.W. Serruys Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients Circulation 109 2004 867 873
5. S.C. Smith Jr., E.J. Benjamin, R.O. Bonow, L.T. Braun, M.A. Creager, B.A. Franklin, R.J. Gibbons, S.M. Grundy, L.F. Hiratzka, D.W. Jones, D.M. Lloyd-Jones, M. Minissian, L. Mosca, E.D. Peterson, R.L. Sacco, J. Spertus, J.H. Stein, K.A. Taubert, and World Heart F, the preventive cardiovascular nurses a AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation Circulation 124 2011 2458 2473
6. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene, and Pravastatin or Atorvastatin E, infection therapy-thrombolysis in myocardial infarction I Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
7. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, and N.K. Wenger Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
8. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl, M. Szarek, and J. Tsai High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
9. Study of the Effectiveness of Additional Reductions in C, Homocysteine Collaborative G, J. Armitage, L. Bowman, K. Wallendszus, R. Bulbulia, K. Rahimi, R. Haynes, S. Parish, R. Peto, and R. Collins Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
10. J.A. de Lemos, M.A. Blazing, S.D. Wiviott, E.F. Lewis, K.A. Fox, H.D. White, J.L. Rouleau, T.R. Pedersen, L.H. Gardner, R. Mukherjee, K.E. Ramsey, J. Palmisano, D.W. Bilheimer, M.A. Pfeffer, R.M. Califf, E. Braunwald, and Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
11. U. Javed, P.C. Deedwania, D.L. Bhatt, C.P. Cannon, D. Dai, A.F. Hernandez, E.D. Peterson, and G.C. Fonarow Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get with the Guidelines (GWTG) Am Heart J 160 2010 1130 1136 1136.e1131-1133
12. S.V. Arnold, P.S. Chan, P.G. Jones, C. Decker, D.M. Buchanan, H.M. Krumholz, P.M. Ho, and J.A. Spertus Translational research investigating underlying disparities in acute myocardial infarction patients' Health status (TRIUMPH): design and rationale of a prospective multicenter registry Circ Cardiovasc Qual Outcomes 4 2011 467 476
13. P.H. Chong Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors Ann Pharmacother 36 2002 1907 1917
14. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N. Merz, C.B. Blum, R.H. Eckel, A.C. Goldberg, D. Gordon, D. Levy, D.M. Lloyd-Jones, P. McBride, J.S. Schwartz, S.T. Shero, S.C. Smith Jr., K. Watson, and P.W. Wilson 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines Circulation 2013
15. K.A. Eagle, M.J. Lim, O.H. Dabbous, K.S. Pieper, R.J. Goldberg, F. Van de Werf, S.G. Goodman, C.B. Granger, P.G. Steg, J.M. Gore, A. Budaj, A. Avezum, M.D. Flather, K.A. Fox, and Investigators G A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733
16. D.K. McGuire, H. Emanuelsson, C.B. Granger, E. Magnus Ohman, D.J. Moliterno, H.D. White, D. Ardissino, J.W. Box, R.M. Califf, and E.J. Topol Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators Eur Heart J 21 2000 1750 1758
17. H.E. Lebovitz Insulin: potential negative consequences of early routine use in patients with type 2 diabetes Diabetes Care 34 Suppl 2 2011 S225 S230
18. S. Nandish, O. Bailon, J. Wyatt, J. Smith, A. Stevens, M. Lujan, and R. Chilton Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence? Curr Atheroscler Rep 13 2011 123 128
19. C.S. Fox, L. Sullivan, R.B. D'Agostino Sr., P.W. Wilson, and Framingham Heart Study The significant effect of diabetes duration on coronary heart disease mortality: the Framingham heart study Diabetes Care 27 2004 704 708
20. J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, D.E. Casey Jr., W.E. Chavey 2nd, F.M. Fesmire, J.S. Hochman, T.N. Levin, A.M. Lincoff, E.D. Peterson, P. Theroux, N.K. Wenger, R.S. Wright, S.C. Smith Jr., A.K. Jacobs, J.L. Halperin, S.A. Hunt, H.M. Krumholz, F.G. Kushner, B.W. Lytle, R. Nishimura, J.P. Ornato, R.L. Page, and B. Riegel ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
21. H.M. Krumholz, J.L. Anderson, B.L. Bachelder, F.M. Fesmire, S.D. Fihn, J.M. Foody, P.M. Ho, M.N. Kosiborod, F.A. Masoudi, and B.K. Nallamothu ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on performance measures (writing committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine Circulation 118 2008 2596 2648
22. P.S. Chan, B.K. Nallamothu, H.S. Gurm, R.A. Hayward, and S. Vijan Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease Circulation 115 2007 2398 2409
23. E. Braunwald Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities N Engl J Med 337 1997 1360 1369
24. S.A. Murphy, C.P. Cannon, S.D. Wiviott, J.A. de Lemos, M.A. Blazing, C.H. McCabe, R.M. Califf, and E. Braunwald Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials) Am J Cardiol 100 2007 1047 1051
25. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, and I. Ford Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
26. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, D.A. DeMicco, P. Barter, C.P. Cannon, M.S. Sabatine, E. Braunwald, J.J. Kastelein, J.A. de Lemos, M.A. Blazing, T.R. Pedersen, M.J. Tikkanen, N. Sattar, and K.K. Ray Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
27. D.D. Waters, J.E. Ho, S.M. Boekholdt, D.A. Demicco, J.J. Kastelein, M. Messig, A. Breazna, and T.R. Pedersen Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes J Am Coll Cardiol 61 2013 148 152
28. Cholesterol Treatment Trialists C, P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, and C. Baigent Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125